Pulmonary Hypertension
CVrg’s extensive coverage of Pulmonary Hypertension, including the sub-indications of pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with hypoxia or lung disease, and pulmonary hypertension associated with left heart disease, provides comprehensive support through the life of your PH assets.
Martha Klovstad, Ph.D.Therapy Area Director,
Heart Failure and Pulmonary Hypertension
Martha received her doctorate in Molecular Biology from Princeton University and completed postdoctoral training at Stanford University. She is an experienced analyst with broad scientific and therapeutic expertise and strong analytical capabilities and leads CVrg’s pulmonary hypertension team.
| CVrg Market Strategies™ |
report
|
Pulmonary Hypertension, 2020–2029 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market landscapes.
KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in PH from CVrg Sentinel, Conference, Insights and Advisory research are also included.
| CVrg Sentinel™ |
monthly updates
|
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of PH assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
| CVrg Conference™ |
expert coverage
|
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why.
| *CVrg KOL Insights™ |
primary research
|
CVrg experts conduct primary research with KOLs in PH, using their critical eyes to evaluate emerging trends, pipelines products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today. *Additional fees may apply.
| CVrg Advisory™ |
answers & new content
|
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in PH drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.